Highest-materiality recent filing
Board authorized management to explore strategic alternatives including sale, merger, financing, or asset dispositions.
Elite Health Systems shareholders approve acquisition of PSS and share increase to 50M
All six proposals passed at Special Meeting on Sept 26, 2025, with quorum of 14.7M votes.
Elite Health Systems to acquire PSS in all-stock deal worth 3.16M shares
Acquires 100% of Physician Support Systems from stockholders including CEO Dr. Prasad Jeereddi (46% owner).
Elite Health Plan subsidiary signs CMS contract for Medicare Advantage Plan, onboarding Oct 2025
On Aug 28, 2025, Elite Health Plan executed CMS contract to operate as an MA/MA-PD organization.
Elite Health Systems appoints Dr. Haranath Policherla as director and Ken Minor as CFO
Dr. Haranath Policherla, age 67, appointed non-executive director effective July 26, 2025.
Elite Health Systems commences $2M-$5M private placement; enters LOI to acquire PSS for 3.16M shares
Private placement of common stock at $0.95/share for gross proceeds of $2M to $5M; proceeds to fund Elite Health Plan and PSS integration.
Elite Health Systems to change OTC ticker from USNU to EHSI effective June 10, 2025
FINRA notified Elite Health Systems on June 9, 2025 that the ticker symbol change request is fully processed.
Elite Health Systems subsidiary gets conditional CMS approval for CY 2026 Medicare Advantage
Elite Health Plan received conditional CMS approval for its CY 2026 Medicare Advantage/MA-PD application on June 3, 2025.
Elite Health Systems subsidiary awarded full-service health plan license in California
Elite Health Plan, wholly owned subsidiary, awarded full-service health care service plan license under Knox-Keene Act on May 29, 2025.
Elite Health Systems ups private placement to $5.5M, issues 480K shares for compensation
Board amended private placement terms to raise up to $5,500,000; $5.05M raised to date at $0.50/share.
Elite Health Systems (f/k/a U.S. Neurosurgical Holdings) changes name, applies for new OTC ticker
Name changed to Elite Health Systems, Inc. effective September 30, 2024 via Delaware certificate of amendment.
U.S. Neurosurgical Holdings names Dr. Prasad Jeereddi CEO; expands private placement to $5M
Charles H. Merriman resigned from the Board effective July 10, 2024; no disagreement cited.
USNU raises $1M in initial close of up to $2M private placement at $0.50/share
Initial closing of private placement raised $1,000,000 from accredited investors at $0.50 per share; second close up to $1,000,000 expected within a month.
USNU acquires remaining 15% of subsidiary USN, issuing 1.39M shares in share exchange
USNU issued 1,392,739 new shares to minority holders of USN, making USN a wholly-owned subsidiary.
Receives 50,000 shares of common stock as director compensation.
U.S. NeuroSurgical swaps auditor Aronson LLC for AJSH & Co LLP; notes material weaknesses
Aronson LLC resigned as independent accountant effective Sept 7, 2022; AJSH & Co LLP engaged Aug 22, 2022 as successor.
U.S. NeuroSurgical Holdings restates Q1 2022 financials; prior statements not reliable
On August 3, 2022, management determined Q1 2022 balance sheet failed to reflect changes from restated FY2021 10-K/A.
U.S. NeuroSurgical Holdings to restate 2021 financials due to $250K tax liability error
2021 consolidated financial statements no longer reliable; restatement required.
USN subsidiary to acquire Elite Health Plan for 15% stake in unit
USN (wholly owned by USNU) issues 300 new shares to Elite Health shareholders, representing 15% of USN post-closing.
the Board unanimously appointed Dr. Prasad A. Jeereddi, age 76, Chief Executive Officer of the Company
Mr. Alan Gold resigned from his positions as President of the Company, effective immediately.
Mr. Charles H. Merriman resigned from his position as a member of the Board and from all of its committees.
On April 17, 2023, the Board of Directors (the “Board”) of U.S. NeuroSurgical Holdings, Inc., a Delaware corporation, (“Company”) unanimously appointed Mr. William St. Lawrence, age 53, as a non-executive director of the Company’s Board, effective immediately.
Max materiality 0.75 · Median 0.65 · Most common event other_material